The oral cavity represents a frontline interface between the external environment and the host immune system. In recent years, the characterization and application of oral immune homeostasis biomarkers detected in saliva have garnered considerable interest as non-invasive diagnostic tools for systemic and oral diseases. This review synthesizes current scientific evidence regarding the epidemiology, pathophysiology, clinical features, diagnostic modalities, and recent advances in the use of salivary biomarkers to assess oral immune status. Emphasis is placed on the clinical relevance of these biomarkers for early disease detection, patient monitoring, and personalized therapeutic strategies in dental and medical practice.
Saliva is a complex biofluid containing a variety of immunologically relevant molecules, including cytokines, chemokines, immunoglobulins, and cellular components. The assessment of biomarkers in saliva offers a promising, minimally invasive approach for monitoring oral and systemic immune homeostasis. Oral immune homeostasis reflects the dynamic equilibrium between host defense mechanisms and commensal microbiota, critically impacting oral and general health. Recent advances in molecular diagnostics, immunoassays, and omics technologies have facilitated the identification of salivary biomarkers relevant to immune regulation, inflammation, and disease processes, thus expanding their clinical utility.
Oral diseases such as periodontitis, gingivitis, and mucosal lesions are prevalent globally, with periodontitis affecting up to 50% of adults and severe forms impacting 10-15%. Systemic diseases, including diabetes mellitus, cardiovascular pathologies, and autoimmune disorders, are increasingly linked to disturbances in oral immune homeostasis. Salivary diagnostic approaches hold particular promise in populations with limited access to invasive testing or in settings where disease monitoring is critical for large groups, such as in public health screening and epidemiological studies. The global burden underscores the need for effective, accessible, and rapid diagnostic tools, with salivary biomarkers representing a compelling avenue for innovation.
Oral immune homeostasis is orchestrated by complex interactions between epithelial barriers, innate and adaptive immune cells, and the oral microbiome. Key mediators include secretory immunoglobulin A (sIgA), defensins, lactoferrin, and pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). Disruption of this balance, whether by pathogenic infection, dysbiosis, or host genetic factors, can result in inflammation, tissue destruction, and progression of both oral and systemic diseases. Alterations in salivary concentrations of these biomarkers reflect changes in local and systemic immune status, providing mechanistic insights into disease pathogenesis and potential therapeutic targets.
Risk factors for altered oral immune homeostasis include poor oral hygiene, smoking, systemic conditions such as diabetes and immunodeficiency, genetic predisposition, advanced age, and high stress levels. Environmental factors, medications affecting salivary flow, and dietary habits also contribute to immune dysregulation in the oral cavity. Identification of these risk factors is crucial for the interpretation of salivary biomarker levels and for tailoring preventive and therapeutic interventions.
Clinical manifestations of disrupted oral immune homeostasis range from asymptomatic inflammatory changes detectable only by biomarker analysis to overt signs such as gingival bleeding, periodontal pocket formation, oral ulcers, and mucosal erythema. In systemic diseases with oral involvement, such as Sjögren’s syndrome or HIV infection, specific patterns of salivary biomarker alterations may precede clinical symptoms, highlighting the diagnostic and prognostic value of these assays.
Salivary diagnostics involve the collection of whole saliva or gland-specific samples, followed by quantitative or qualitative analysis of immune biomarkers using enzyme-linked immunosorbent assay (ELISA), multiplexed bead-based assays, or high-throughput omics platforms. Biomarkers such as sIgA, IL-1β, IL-6, matrix metalloproteinases (MMPs), and C-reactive protein (CRP) have been validated in research and increasingly in clinical settings for the diagnosis and monitoring of periodontitis, caries risk, oral cancer, and systemic inflammatory conditions. Standardization of collection protocols, normalization to salivary flow rates, and establishment of reference ranges are critical for clinical translation.
Monitoring oral immune biomarkers provides clinicians with actionable data to guide individualized treatment strategies. For example, elevated salivary IL-1β or MMP-8 may prompt intensified periodontal therapy, while persistent inflammatory signatures in saliva could indicate suboptimal response to interventions and necessitate further systemic evaluation. Patient education, risk modification, antimicrobial therapies, and adjunctive immunomodulatory agents are informed by biomarker profiles, supporting precision medicine approaches in dental care.
Recent developments include point-of-care devices for chairside measurement of salivary biomarkers, integration of artificial intelligence for predictive analytics, and exploration of novel biomarker candidates via proteomics, transcriptomics, and metabolomics. Research is ongoing into the use of exosomal cargo as a source of stable, disease-specific biomarkers. These advances promise to enhance early detection, risk stratification, and monitoring of disease progression in a broad spectrum of oral and systemic conditions.
Major dental and medical associations now recognize the importance of oral-systemic health links and advocate for the incorporation of salivary diagnostics in comprehensive patient assessments. Expert consensus recommends the use of validated salivary biomarkers for risk assessment in periodontal disease, screening for caries susceptibility, and monitoring therapy response in selected populations. Ongoing efforts aim to harmonize testing methodologies, reporting standards, and clinical decision algorithms to facilitate widespread adoption.
The integration of oral immune homeostasis biomarkers into salivary diagnostics represents a paradigm shift in preventive, diagnostic, and therapeutic strategies for oral and systemic diseases. These non-invasive biomarkers reflect underlying pathophysiological processes, enable early detection, guide personalized interventions, and support longitudinal disease monitoring. Continued research and standardization will be essential to maximize clinical utility and realize the promise of salivary biomarker-guided care in routine medical and dental practice.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation